Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes
BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro. The aim of this trial is to assess the efficacy and safety of BioChaperone® Combo in subjects with type 1 diabetes under a dose of…
- Trial name
- NCT01981031
- Testing
- BioChaperone® Combo, Humalog® Mix25
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus
Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas.
- Trial name
- NCT03272269
- Testing
- IMCY-0098
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 41 people
- Sponsor
- Imcyse SA
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia
This study is conducted in Asia. The aim of this study is to evaluate the overall acceptance of healthcare professionals (nurses and doctors) to the NovoLet® system used in a hospital environment.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492205
- Testing
- insulin human
- Where
- Indonesia
- Volunteers
- 203 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of L03TD1 in healthy volunteers.
- Trial name
- NCT07533539
- Testing
- L03RD1, L03RD2, L03TD1
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celltrion
Diabetes Mellitus
Safety of Bosentan in Type II Diabetic Patients
This study evaluates the safety of topical Bosentan in Type II Diabetes patients
- Trial name
- BOSRET (NCT04068272)
- Testing
- Bosentan
- Where
- 2 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Retinset SL
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Diabetes, Diabetes Mellitus, Type 1
A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02117622
- Testing
- insulin degludec
- Where
- 38 sites in India
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Insulin Glulisine, Diabetes Mellitus Type 1
To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy
- Trial name
- NCT00397553
- Testing
- Insulin glulisine
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Sanofi
Type 1 Diabetes
Performance Study of the SOLO 2.0 Insulin Pump
The Purpose of the study is to to evaluate the performance of the SOLO (version 2.0) micropump insulin delivery system, in Type 1 diabetic patients who use insulin pumps for their treatment.
- Trial name
- NCT01500928
- Testing
- SOLO insulin pump
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Medingo Ltd
Diabetes, Diabetes Mellitus, Type 1
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes
This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240.
- Trial name
- NCT01486381
- Testing
- biphasic insulin aspart 30
- Where
- 2 sites in South Africa
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Trial name
- NCT00332826
- Testing
- Technosphere Insulin
- Where
- 78 sites in United States, Argentina and 9 more
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
Uveal Melanoma, Liver Metastases
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.
- Trial name
- CLEVER (NCT03408587)
- Testing
- CVA21, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Viralytics
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB
Type 1 Diabetes, Type 1 Diabetes (T1D)
Study of IMC-S118AI in Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
- Trial name
- NCT07493122
- Testing
- IMC-S118AI
- Volunteers
- 154 people
- Sponsor
- Immunocore Ltd
Type 1 Diabetes
Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune…
- Trial name
- NCT02354911
- Testing
- Immunoregulatory Dendritic Cells
- Sponsor
- DiaVacs, Inc.
Diabetes Mellitus, Type 1
PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males
Primary objective: To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan \& Lee Insulin Aspart Injection with both EU-approved NovoRapid® and US-licensed NovoLog® (Reference Products) in healthy male…
- Trial name
- NCT04237129
- Testing
- Gan & Lee Insulin Aspart
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Diabetes Mellitus, Type 1
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT05131139
- Testing
- Continuous Glucose Monitoring System
- Where
- 4 sites in United States
- Volunteers
- 350 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
The purpose of this study is to measure how much of the study drug or insulin glargine gets into the blood stream and how long it takes the body to get rid of it. The effect of exercise will also be evaluated.
- Trial name
- NCT01784211
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
- Trial name
- CREATE-1 (NCT05626712)
- Testing
- CELZ-201 Administration, Control Group
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Creative Medical Technology Holdings Inc